اسهم بشائر الخير

بشائر الخير

عضو نشط
التسجيل
18 سبتمبر 2007
المشاركات
247
السهم الاول

DecisionPoint Systems, Inc. (OTCBB: DNPI)




DecisionPoint Systems, Inc.
DecisionPoint builds enterprise wireless and mobile computing solutions for customers’ needs. In a nutshell, they bring the field workers into to office in real time or you can think of it as bringing the office into the field. Crucial information and transactions are transmitted in real time improving accuracy and efficiency for the client. DecisionPoint provides a win-win solution.

The enterprise mobile computing industry has standardized several key technologies over the past five years and DecisionPoint has been front and center in this evolutionary process in adapting mobile units to customer’s needs. DescisionPoint has been an established company in this industry and when opportunity knocked in the Field Mobility niche Decision Point was prepared to answer the call.

DecisionPoint’s strategy in their target market is to enable the DecisionPoint customer to focus on their mission — THEIR business, not the technology. This is accomplished by providing mission-critical systems, seamless connectivity through highly reliable voice and data networks and a suite of advanced and/or custom applications that provide real-time information to end users.

Tier One Customer List: Success breeds success and with Tier One retail customers including: Liz Claiborne, PETCO Animal Supplies, Nike, Nordstrom and Grocery Outlet; DecisionPoint has a strong foundation. Manufacturing companies include Dade Behring (Division of Siemens), Sargent Manufacturing (Division of ASSA Abloy), Timken Corp., Swiss Army Brands, Smith & Wesson and pharmaceutical companies such as Pfizer and Celgene.

A high barrier to entry enhances DecisionPoint’s position in the industry as it rides the crest of the wave of the latest MUST HAVE technology for modern enterprise with a national footprint and established relationships.

Revenue Stream
DecisionPoint’s revenue stream is broad and pervasive –

First, from normal business transactional equipment and service sales;
Second, from extended maintenance and services contracts with a monthly, pro-rata portion of revenue recognized over the life of the contract, usually from one to three years and;
Third, from recurring monthly revenue for a typical managed service project usually over a minimum of one year to two years.
 

بشائر الخير

عضو نشط
التسجيل
18 سبتمبر 2007
المشاركات
247
السهم الثاني


Energy Systems Corporation (OTCBB: DYMTF)

Press Release
Source: Dynamotive Energy Systems Corporation
On Thursday September 3, 2009, 12:52 pm EDT
Buzz up! 0 Print
VANCOUVER & MCLEAN, Va.--(BUSINESS WIRE)--Dynamotive today provided an update on CQuest™ BioChar test programs, production and US opportunities.

Dynamotive Energy Systems Corporation (OTCBB: DYMTF - News), a leader in second generation biomass-to-biofuel technology and BlueLeaf Inc., a Canadian private social purpose enterprise active in applied research concerning the environment, are pleased to provide a mid-season report for the second year of the BlueLeaf commercial farming field trial begun and reported in 2008. The findings further support the economic potential for CQuest Biochar as soil enhancer. CQuest Biochar is a by-product of the BioOil® production process and represents approximately 25% of the total product output of a plant.

Dynamotive is currently producing CQuest Biochar at its plant in West Lorne and is distributing it to users in bulk and in drums for soil application. The Company has plans for development of a plant in the US where it has secured long term biomass supply contracts. For further information on BioChar and Dynamotive please visit www.dynamotive.com.
 

بو سجي

عضو نشط
التسجيل
2 فبراير 2008
المشاركات
1,407
الإقامة
السره
يمكن الاسم في غلط موراضي يطلع عندي
 

بشائر الخير

عضو نشط
التسجيل
18 سبتمبر 2007
المشاركات
247
السهم الثالث ولاروع باذن الله تعالى عزوجل

Impact Fusion International Inc. (IFUS.PK)


Source: Impact Fusion International, Inc.
On Friday September 4, 2009, 6:30 am EDT
Buzz up! 0 Print
Companies:Impact Fusion International Inc.
DEERFIELD BEACH, FL--(Marketwire - 09/04/09) - Impact Fusion International Inc. (Pinksheets:IFUS - News) announced today it has developed a healthy Energy Shot drink called Mastic Blast(TM).

Mastic Blast(TM) is an all natural energy shot that tastes great, has no caffeine or artificial stimulants, contains 18 amino acids with the highest level of electrolytes and provides sustained energy without raising heart rates.

Mastic Blast(TM) also contains our proprietary formula Nutri-Mastic(TM) that delivers all the natural benefits with no "crash."

"Mastic Blast(TM) is the third revenue producing category announced by the Company designed to catapult the Company into high top end revenues and bottom line profits. The addition of this product line is consistent with the three year business model which plans for the Company to become a powerhouse in product, profit and drive the sales projections to $78 million by the end of our third fiscal year," stated Marc Walther, CEO. "With our experienced team, lead by Boost Management, LLC, our newly retained energy drink expert, our goal will be for our brand and distribution network to be well established prior to manufacturing launch," continued Mr. Walther.

According to articles published in The New York Times, the most popular power drink costs 20 times as much per ounce as the most popular branded soft drink, comes in a tiny bottle and tastes so bad that most people hold their nose and down it in a single gulp. Despite the recession, energy shots are soaring in sales and are the hottest selling drink category in the country. Current market sector sales are expected to almost double this year from last to about $700 million.
 

بشائر الخير

عضو نشط
التسجيل
18 سبتمبر 2007
المشاركات
247
got stocks
ones to watch


find out what small-cap / micro-cap's to add to your radar. Get the news and information that moves the markets this week and the "ones to watch. The "quality" is back in stocks...



Axial vector energy corp. (axvc.pk)
buy 1.70
edoorways corp. (edwy.pk)
buy .0220
kraig biocraft laboratories, inc. (kblb.ob)
buy .o10







في اسهم من هذه السهم راح نجدد العقد معها باذن الله عزوجل بس هى


ماراح ندش الا في وقته

فكرو فيها
وعطونا توقعاتكم ماتتضح الا ثاني يوم تداول ماشي يااخوان



والتوفيق معا الله عزوجل وتصبحون على خير
 

nouf

عضو نشط
التسجيل
7 يوليو 2008
المشاركات
805
الإقامة
الكويت
السهم الثالث طلع غلط معي ياريت تكتب مره ثانيه؟؟؟؟؟؟؟؟
 

Abonada

عضو نشط
التسجيل
6 يونيو 2007
المشاركات
674
الإقامة
الكويت

بشائر الخير

عضو نشط
التسجيل
18 سبتمبر 2007
المشاركات
247
هلا وكل هلا بالاخوان والاخوات


بوسجى abonada nouf

تشكرون على المشاركه وفالكم الخير بشهر الخير:D
 

nouf

عضو نشط
التسجيل
7 يوليو 2008
المشاركات
805
الإقامة
الكويت
اخ بشائر الخير عندك سهم تتوقع له انطلاقه خلال هذا الاسبوع؟؟؟؟؟؟؟؟
 

بشائر الخير

عضو نشط
التسجيل
18 سبتمبر 2007
المشاركات
247
اخ بشائر الخير عندك سهم تتوقع له انطلاقه خلال هذا الاسبوع؟؟؟؟؟؟؟؟



انشاالله راح تشوف كل خير باذن الله الاسهم التي ذكرناها سابقا راح باذن الله تتحرك هذه الاسبوع لان فيه اخبار حلوه بس راح اعطيك بعد واحد حلوووووووو باذن الله عزوجل :eek:
 

بشائر الخير

عضو نشط
التسجيل
18 سبتمبر 2007
المشاركات
247
سهم طيب عليه اخبار حلوووووووه والله يرزقكم اجمعيين

GENOVA BIOTHERAP INC (GVBP.OB)

Press Release
Source: GENova Biotherapeutics, Inc.
On Friday September 4, 2009, 9:00 am EDT
Buzz up! 0 Print
NEW YORK, NY, Sept. 4 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB - News) - GENova Biotherapeutics, Inc., ("GENova"), a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, today named Dr. John Savin as its Vice President.

Dr. Savin will work closely with the CEO to direct GENova's growth in its business of identifying and acquiring potential drug targets and then subsequently outsourcing them to partners who can successfully usher them through clinical trials and then bring them to market.

"I am honoured to guide GENova as it positions itself as a leader in the expeditious development of innovative drugs," said Dr. Savin. "I am confident that the GENova business model will deliver new and effective therapies for patients while maximizing value for shareholders."

About John Savin, B.Sc, Ph.D., MBA

Mr. Savin builds on his 20 years experience in marketing and finance to provide strategic direction in the commercialisation and funding of innovative science on behalf of high-potential companies. His previous role was CEO of Physiomics, a systems biology company that he founded. Physiomics entered collaborations with companies like Bayer and Cyclacel, and developed a sophisticated product to optimize cancer therapeutic development. His company listed on AIM in 2004.

Prior to that, Savin worked for investment bank Gerrard Group as a pharmaceutical and biotechnology investment analyst, soon becoming a Director and a top-10-ranked City analyst. In this role, he worked with corporate finance on venture capital, many IPOs, secondary fund raising, restructuring and due diligence. Other experience includes being a Senior Consultant working at Board level with Glaxo, Zeneca, the MRC and Cabinet Office and DTi looking at issues such as the commercialization of humanized monoclonals and the strategic impact of the human genome project; and serving as International Product Manager for Pharmacia Biotech (Sweden) and Amersham International (UK). In addition to his current consulting role, Savin also writes investment research on listed biotechnology and medical devices companies. He has a B.Sc in Bioscience and Chemistry, an M.B.A. in Strategic Management, and a Ph.D in Organic Chemistry.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec. Visit GENova online at: www.genovabio.com.





انشالله راح نشوف اسبوع حافل باذن الله عزوجل
 

مضارب ضايع

عضو نشط
التسجيل
28 سبتمبر 2008
المشاركات
869
السلام عليكم اخوي بشاير الخير اذا ممكن نعرف سعر الدخول والستب لوز لهذهالاسهم فضلا وليس امرا تقبل مني جزيل التحايا
 

بشائر الخير

عضو نشط
التسجيل
18 سبتمبر 2007
المشاركات
247
Gvbp سعر الشراء 0.100 ستوب لوز 0.090 الهدف الاول بأذنالله عزوجل 0.250

ملاحظه استوب لوز يزيد يوم عن يوم

Dnpi سعر الشراء من 0.45 الى 0.50 ستوب لوز 0.40 الهدف الاول باذن الله عزوجل 0.70 الهدف الثاني انشالله 0.90 وفي النهايه في فجوه عند 0.125 باذن الله يوصله يامن فوق يمن تحت
dymtf السهم هذه للاستثمار ممتاز الشراء من 1.77 الى 2.00


ifus
وفي الختام السهم على المحك اذا كسر 0.150 راح تشوفه باذن الله0.450 باذن الله راح تشوفه والعلم عند الله جل جلاله
 

بشائر الخير

عضو نشط
التسجيل
18 سبتمبر 2007
المشاركات
247
سهم طيب عليه اخبار حلوووووووه والله يرزقكم اجمعيين

genova biotherap inc (gvbp.ob)

press release
source: Genova biotherapeutics, inc.
On friday september 4, 2009, 9:00 am edt
buzz up! 0 print
new york, ny, sept. 4 /prnewswire-firstcall/ - (otcbb: Gvbp.ob - news) - genova biotherapeutics, inc., ("genova"), a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, today named dr. John savin as its vice president.

Dr. Savin will work closely with the ceo to direct genova's growth in its business of identifying and acquiring potential drug targets and then subsequently outsourcing them to partners who can successfully usher them through clinical trials and then bring them to market.

"i am honoured to guide genova as it positions itself as a leader in the expeditious development of innovative drugs," said dr. Savin. "i am confident that the genova business model will deliver new and effective therapies for patients while maximizing value for shareholders."

about john savin, b.sc, ph.d., mba

mr. Savin builds on his 20 years experience in marketing and finance to provide strategic direction in the commercialisation and funding of innovative science on behalf of high-potential companies. His previous role was ceo of physiomics, a systems biology company that he founded. Physiomics entered collaborations with companies like bayer and cyclacel, and developed a sophisticated product to optimize cancer therapeutic development. His company listed on aim in 2004.

Prior to that, savin worked for investment bank gerrard group as a pharmaceutical and biotechnology investment analyst, soon becoming a director and a top-10-ranked city analyst. In this role, he worked with corporate finance on venture capital, many ipos, secondary fund raising, restructuring and due diligence. Other experience includes being a senior consultant working at board level with glaxo, zeneca, the mrc and cabinet office and dti looking at issues such as the commercialization of humanized monoclonals and the strategic impact of the human genome project; and serving as international product manager for pharmacia biotech (sweden) and amersham international (uk). In addition to his current consulting role, savin also writes investment research on listed biotechnology and medical devices companies. He has a b.sc in bioscience and chemistry, an m.b.a. In strategic management, and a ph.d in organic chemistry.

About genova biotherapeutics inc.

Genova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to big pharmaceutical and biotechnology companies such as pfizer, amgen, myriad genetics, medarex, and biogen idec. Visit genova online at: www.genovabio.com.





انشالله راح نشوف اسبوع حافل باذن الله عزوجل







اربط حزامك معاه :d
 

بشائر الخير

عضو نشط
التسجيل
18 سبتمبر 2007
المشاركات
247
Genova files patent for new prostate cancer treatment
PR Newswire(Tue 10:03am)



Source: GENova Biotherapeutics, Inc.
On Tuesday September 8, 2009, 10:03 am EDT
Buzz up! 0 Print
NEW YORK, Sept. 8 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB - News) - GENova Biotherapeutics, Inc., ("GENova"), is pleased to announce that it has filed a patent for a novel peptide that disrupts the advance of prostate cancer and thus has blockbuster potential as a new anti-cancer drug.

The peptide, called Prostaganin, is a 21-amino compound which is highly reactive to prostate cancer cells, and has the ability to specifically target them. In laboratory experiments, Prostaganin has demonstrated an ability to preferentially bind to and disrupt certain negatively charged components of the membranes of prostate cancer cells.

Prostaganin thus has tremendous potential as a superior new form of treating prostate cancer. Current treatment methods such as surgery, radiation and chemotherapy are outmoded, unsatisfactory, and have severe side effects. Prostaganin offers a positive alternative. The peptide, bio-engineered from naturally occurring compounds in the human body, can target and destroy cancerous cells, whilst leaving surrounding healthy tissues intact, and causing no undesirable side effects. Further development of this novel peptide could revolutionize the way people fight cancer.

The demand for new and better treatments for prostate cancer has never been higher. Prostate cancer presently accounts for 30% of all the major cancers in men. The Prostate Cancer Foundation states that prostate cancer is the cancer with the largest expected increase in the next decade, and that annual incidence of the cancer will rise to 300,000 cases in the U.S. alone by 2015.

"Prostaginin represents a significant milestone in GENova's business agenda to acquire patents for the most innovative new cancer treatments," says Aaron Whiteman, CEO of GENova, "But most importantly, it represents a new generation of cancer treatments that could save millions of lives, and treat prostate cancer in men with no side effects or adverse effects on quality of life. The implications are tremendous." Licensing to companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec could prove to be extremely lucrative in the short and long term. GENova works very hard on a daily basis to close agreements with big Biotechnology players in the industry.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies. Visit GENova online at www.genovabio.comForward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.
 

بشائر الخير

عضو نشط
التسجيل
18 سبتمبر 2007
المشاركات
247
في اسهم من هذه السهم راح نجدد العقد معها باذن الله عزوجل بس هى


ماراح ندش الا في وقته

فكرو فيها
وعطونا توقعاتكم ماتتضح الا ثاني يوم تداول ماشي يااخوان



والتوفيق معا الله عزوجل وتصبحون على خير


EDWY مبروك للي ماسك اليوم كسر 0.0530 المقاومه الاول وبين انه ضعيف عند 0.070 وبعدها مايرده 0.500 :eek: والله اعلم الف مبروك دربك خضر خضر
 
أعلى